About Evolab
Evolab is a company based in Denver (United States) founded in 2014 was acquired by CBx Sciences in January 2018. Evolab offers products and services including Alchemy Live, Alchemy, Chroma, and Delta 8. Evolab operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Denver, United States
- SectorsHealthcare
- Website category Health · Addictions
- Email••••••••
- Website evolab.com
- Social LinkedIn X Facebook Instagram
- Acquired by CBx Sciences (Jan 2018)
- Investors
- Acquired byCBx Sciences
(Jan 2018)
Products & Services of Evolab
Evolab offers a comprehensive portfolio of products and services, including Alchemy Live, Alchemy, Chroma, and Delta 8.
Liquid resin from flash-frozen flower for full-spectrum cannabis effects.
Terps blended with CO2 distillate for strain-specific flavors and experiences.
Cannabinoid mix with cannabis terpenes for consistent and effective effects.
Extracted Delta 8 for clear, focused highs using CO2 purification methods.
Investors in Evolab
Evolab has secured backing from 1 investor. Prominent investors backing the company include CBx Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cannabinoid-based oils, skincare, vapes, and related products are provided. | 2016 | cbxsciences.com | Denver, United States |
Investor details for Evolab
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Evolab
2 dated milestones of Evolab across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Evolab is founded.
- Exit Acquired by CBx Sciences.
Competitors of Evolab
Evolab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Evolab
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evolab
Websites that share an audience with Evolab (evolab.com).
- Global rank#8,547,240
among all websites
- Category rank#5,329
Health · Addictions
- Bounce rate45%
- Pages per visit1.8
- Average visit35 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Evolab. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| silverstemcannabis.com | 100% | 80.1K | #299,328 | View details |
Latest news on Evolab
Complete news archive for Evolab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Evolab
10 companies that operate in the same segment as Evolab (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Evolab
Evolab was founded in 2014.
Evolab is headquartered in Denver, United States. It is registered at Denver, Colorado, United States.
Founded in 2014 in Denver, United States, Evolab operates in the biotechnology sector focused on cannabis extraction. Novel CO2 technology is utilized to preserve bioactive compounds, enabling terpene isolation at up to 99 purity. Cannabis-derived terpenes and essential oils are sold under brands including Chroma, FreshTerps, and Alchemy. Collaboration with GW Pharmaceuticals is underway for cannabinol delivery via transdermal skin patches.
Evolab's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Evolab offers Alchemy Live, Alchemy, Chroma, and Delta 8.
Evolab has 1 investor. Key investors include CBx Sciences.
Yes. Evolab was acquired by CBx Sciences in January 2018.